Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.96 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.96 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.96 |
| ▸ | CRYZ | Q08257 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclophosphamide Anhydrous SCHEMBL28088100 | 1.00 | NPSR1 (1.00) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL14192809 | 1.00 | NPSR1 (1.00) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL4346 | 1.00 | NPSR1 (1.00) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL5328735 | 1.00 | NPSR1 (1.00) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL1285823 | 1.00 | NPSR1 (1.00) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL20542636 | 1.00 | NPSR1 (1.00) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL4994883 | 0.98 | NPSR1 (0.96) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL5802618 | 0.98 | NPSR1 (0.96) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL6071 | 0.98 | KDM4E (1.00) | NPSR1KDM4EALOX15MAPK1CRYZ | |
| Cyclophosphamide Anhydrous SCHEMBL5436000 | 0.98 | KDM4E (1.00) | NPSR1KDM4EALOX15MAPK1CRYZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 67881 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-3727367-B1 | VITAMIN K2 COMPOSITIONS FOR USE IN THE TREATMENT OF DRUG INDUCED NEUROPATHY | SYNERGIA LIFE SCIENCES PVT LTD (IN) | 2026-05-27 | — | — | EP | claimed |
| WO-2026107350-A1 | NUTRITION EVALUATION AND RECOMMENDATION SUPPORTED BY MITOCHONDRIAL ENZYME TESTING | MASTERJOHN CHRISTOPHER (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4745155-A1 | POWDER CONTAINING PARTICLES OF GELATIN DERIVATIVE AND APPLICATION OF SAME IN MEDICAL TREATMENT | National Institute for Materials Science (JP) | 2026-05-20 | — | — | EP | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| EP-4743490-A1 | HUMANIZED ANTI-CD7 ANTIBODY | Christian-Albrechts-Universität zu Kiel (DE) | 2026-05-20 | — | — | EP | claimed |
| US-20260134972-A1 | Nutrition Evaluation and Recommendation Supported by Mitochondrial Enzyme Testing | MASTERJOHN CHRISTOPHER (US) | 2026-05-14 | — | — | US | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4054541-B1 | SALT FORMS OF A COMPLEMENT COMPONENT C5A RECEPTOR | CHEMOCENTRYX INC (US) | 2026-05-06 | — | — | EP | claimed |
| EP-3978473-B1 | COMPOUND CONTAINING AN INDOLEACETIC ACID CORE STRUCTURE AND USE THEREOF | BEIJING AN JIAN XI BIO MEDICAL TECH CO LTD (CN) | 2026-05-06 | — | — | EP | claimed |
| EP-0019167-B1 | MEDICINAL PREPARATION FOR THE TREATMENT OF CARCINOMA AND PROCESS FOR PREPARING IT | Limburg, Hans, Dr. (DE) | 1983-10-12 | — | — | EP | claimed |
| EP-0083600-A1 | Use of alkaloid derivatives for the manufacture of a medicament for the strengthening of the immune system and for the treatment of viral, bacterial and fungal infections. | NOWICKY WASSILI | 1983-07-20 | — | — | EP | claimed |
| EP-0007206-B1 | PHENETHANOLAMINES, THEIR FORMULATIONS, PREPARATION AND USE | ELI LILLY AND COMPANY (US) | 1983-02-23 | — | — | EP | claimed |
| WO-1983000486-A1 | METHOD FOR THE DIAGNOSTIC AND THE THERAPEUTIC TREATMENT OF TUMORS AND/OR INFECTIOUS DISEASES OF ALL SORTS BY THE USE OF ALKALOID COMPOSITIONS OR THE SALTS THEREOF | NOWICKY, WASSYL | 1983-02-17 | — | — | WO | claimed |
| EP-0003750-B1 | SALTS OF DITHIODIALKANESULFONIC ACIDS FOR USE IN CYTOSTATIC THERAPY WITH ALKYLATING AGENTS | Asta-Werke Aktiengesellschaft Chemische Fabrik (DE) | 1981-04-15 | — | — | EP | claimed |
| EP-0007206-A1 | Phenethanolamines, their formulations, preparation and use | ELI LILLY AND COMPANY (US) | 1980-01-23 | — | — | EP | claimed |
| EP-0003750-A1 | Salts of dithiodialkanesulfonic acids for use in cytostatic therapy with alkylating agents | Asta-Werke Aktiengesellschaft Chemische Fabrik (DE) | 1979-09-05 | — | — | EP | claimed |
| EP-0002495-A1 | Composition for use in cytostatic therapy | Asta-Werke Aktiengesellschaft Chemische Fabrik (DE) | 1979-06-27 | — | — | EP | claimed |
| US-4106488-A | Cancer treatment method | GORDON, DAVID, SKOKIE, ILLINOIS | 1978-08-15 | — | — | US | claimed |
| US-3987166-A | TREATMENT OF TUMORS WITH GLUCAN COMPOSITIONS IN MICE AND RATS | KAKEN KAGAKU KABUSHIKI KAISHA (JA) | 1976-10-19 | — | — | US | claimed |